Cancer Cardiovascular Disease Transplant 
DAIC
FEBRUARY 2, 2024
The event is offered as an interdisciplinary and interspecialty course to provide clinicians and researchers with the tools needed to improve the cardiovascular (CV) health of cancer patients in everyday practice. 9-11, 2024, with program planners preparing a robust program. The opening Plenary session, “Perspective from the U.S.
Stroke Journal
JANUARY 30, 2025
Initially, CHIP was identified as a risk factor for hematologic cancer, but recently, many studies have implicated it as a risk factor for cardiovascular disease. congenic mice were transplanted with suspensions of bone marrow cells containing 10% CD45.1-/CD45.2+ We used the C57BL/6 congenic mice that express the CD45.1
Journal of the American Heart Association
MARCH 3, 2025
Moderators assessed were sample demographics (age, body mass index, sex, and time since T2D diagnosis) and cardiovascular outcomes (eg, echocardiographic variables, blood pressure).ResultsAbsolute ResultsAbsolute (cohorts n=30; subjects n=1152; mean difference, 0.29 L/min [95% CI, 0.37 mL/kg per min; 95% CI, 6.94
Cardiometabolic Health Congress
MARCH 8, 2024
Centers for Disease Control and Prevention and as a behavioral sciences intern at the American Cancer Society. Morris, MD: Board-certified in internal medicine, cardiovascular diseases, cardiac computed tomography, and clinical lipidology. Dr. Stanford has served as a health communications fellow for the U.S.
Dr. Malcolm Kendrick
OCTOBER 30, 2024
The hypothesis that a raised cholesterol level causes heart disease [atherosclerotic cardiovascular disease (ASCVD)] is possibly the single most powerful idea in medicine. Which remains the single most influential study on cardiovascular disease, ever. At least some of it. It was simply a matter of time.
Expert insights. Personalized for you.
95 
Let's personalize your content